Steven Gannon - 14 Jun 2023 Form 4 Insider Report for Fusion Pharmaceuticals Inc.

Role
Director
Signature
/s/Maria Stahl as Attorney-in-Fact for Steve Gannon
Issuer symbol
N/A
Transactions as of
14 Jun 2023
Net transactions value
$0
Form type
4
Filing time
14 Jun 2023, 17:07:44 UTC
Previous filing
02 Jun 2023
Next filing
08 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +17,000 $0.000000 17,000 14 Jun 2023 Common Stock 17,000 $4.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc.